Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) FCF Margin (2019 - 2023)

Alx Oncology Holdings' FCF Margin history spans 4 years, with the latest figure at 9596.63% for Q4 2023.

  • For Q4 2023, FCF Margin rose 41091.0% year-over-year to 9596.63%; the TTM value through Dec 2023 reached 8411.37%, down 2967686.0%, while the annual FY2025 figure was 5265.54%, 181132.0% down from the prior year.
  • FCF Margin for Q4 2023 was 9596.63% at Alx Oncology Holdings, up from 7635.81% in the prior quarter.
  • Across five years, FCF Margin topped out at 1545650.0% in Q3 2022 and bottomed at 1538.14% in Q2 2020.
  • The 4-year median for FCF Margin is 8313.87% (2023), against an average of 263045.76%.
  • The largest YoY upside for FCF Margin was 41091bps in 2023 against a maximum downside of -153801419bps in 2023.
  • A 4-year view of FCF Margin shows it stood at 231.82% in 2019, then tumbled by -564bps to 1538.14% in 2020, then surged by 697bps to 9185.71% in 2022, then grew by 4bps to 9596.63% in 2023.
  • Per Business Quant, the three most recent readings for ALXO's FCF Margin are 9596.63% (Q4 2023), 7635.81% (Q3 2023), and 8991.94% (Q2 2023).